piperacillin + tazobactam

Piperacillin + tazobactam is a fixed-dose combination antibiotic consisting of the broad-spectrum ureidopenicillin piperacillin and the β-lactamase inhibitor tazobactam. Piperacillin acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Tazobactam inhibits many β-lactamases produced by Gram-negative and some Gram-positive bacteria, thereby protecting piperacillin from enzymatic degradation and extending its antibacterial spectrum. This combination is active against a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria—including Pseudomonas aeruginosa—and is used for moderate to severe infections such as intra-abdominal infections, lower respiratory tract infections (including hospital-acquired pneumonia), urinary tract infections, skin/soft tissue infections, gynecological infections (e.g., pelvic inflammatory disease), bone/joint infection, bacteremia/sepsis, as well as for perioperative prophylaxis in certain high-risk surgeries[1][2][4][5]. It is administered intravenously. The drug was first approved in 1993 in the United States[1][2]. It appears on the WHO Model List of Essential Medicines.

Brand names

TazocinZosyn达梭霉素

Other names

哌拉西林/他唑巴坦哌拉西林钠他唑巴坦钠piperacillin/tazobactam